Nancy Valente, M.D.

Director
Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development. She most recently served as a senior vice president at Genentech, a member of the Roche Group, and as its global head and co-lead of global product development of its oncology and hematology therapeutic area. Dr. Valente was responsible for setting the strategy for the oncology/hematology product development department, including clinical development, collaboration activities and budget management. She played a critical role in the development of new therapies for patients with serious illnesses, including the approvals of Gazyva®, Venclexta®, Polivy® and Hemlibra®. Dr. Valente has held various positions with increasing responsibilities at Genentech and then at Roche after Genentech was acquired by Roche, including vice president for global product development for oncology, hematology franchise and senior group medical director, leader for hematology development. Prior to Genentech, she served in senior-level positions at Anosys, Inc. and Coulter Pharmaceutical, Inc., and earlier in her career, she held academic positions at the University of California, San Francisco (UCSF). Dr. Valente serves on the Boards of Directors of Myovant Sciences GmbH and Immatics N.V. Dr. Valente received her M.D. from the University of Missouri and completed her internal medicine training at Oregon Health & Science University, followed by fellowships in hematology at Stanford University and oncology at UCSF.
Independent Director